Dr. Janet Chollet

Dr. Janet A. Chollet is a board-certified obstetrician–gynecologist, biotech co-founder, and translational medicine leader based in Boston. She is also the Co-Founder and Chief Medical Officer of Procyrn LLC, where she guides the development of sustained-release hydrogel immune therapeutics and reformulated antivirals. Her focus is on maternal–fetal health, neuroinflammation, and HPV-related cervical disease.

Her professional path spans three decades, combining clinical practice, academic roles, and translational research. Over the years, Dr. Chollet has built a career that bridges patient care and medical innovation. She has practiced at respected institutions such as Beth Israel Deaconess Medical Center and the University of Pittsburgh. Alongside her work in medicine, she holds three U.S. patents in women’s health drug delivery and has contributed to advancing multiple preclinical and early-stage clinical programs.

Janet Chollet began her academic journey with a Bachelor of Science in Neuroscience from the University of California, Santa Barbara in 1986. Drawn to the connection between science and human health, she pursued her Doctor of Medicine degree at New York Medical College and completed her studies in 1991. She then entered the demanding residency program in Obstetrics and Gynecology at LAC/USC Women’s Hospital, where she trained from 1991 to 1995. These early years established her lifelong dedication to developing therapeutic options that improve the lives of women, children, and families.

Following residency, Dr. Chollet joined Magee-Women’s Hospital, affiliated with the University of Pittsburgh, as a staff physician and instructor. From 2000 through 2007, she cared for patients while teaching and mentoring medical trainees. These responsibilities allowed her to refine her vision of translational medicine as a bridge between clinical practice and therapeutic innovation. In 2007, she joined Beth Israel Deaconess Medical Center in Boston, where she continues her work as an obstetrician–gynecologist and remains engaged in academic training. Her clinical work is closely connected with her interest in translational research, and she has continued to bring these two aspects of her career together.

Her efforts in this area resulted in three issued U.S. patents related to topical and vaginal drug delivery:
US 9,693,953 — Method of treating atrophic vaginitis
US 9,675,546 — Method of treating atrophic vaginitis with triphenylethylene derivatives
US 9,480,662 — Compositions and methods for topical tamoxifen citrate therapy

This portfolio of work became central to Pear Tree’s eventual merger with Dare Bioscience (NASDAQ: DARE), a company with a broader pipeline in women’s health therapies.

In 2023, Janet Chollet, MD, co-founded Procyrn LLC, a Boston-based biotechnology company focused on sustained-release biologics and reformulated antivirals. As Chief Medical Officer, she directs clinical development, translational strategy, and regulatory planning. Procyrn distinguishes itself through its emphasis on applying drug delivery science to unmet medical needs in maternal–fetal health, neuroinflammation, and HPV-driven cervical disease.

In addition, Dr. Janet Chollet is exploring an early-stage concept: Autism Prevention Through Maternal–Fetal Immune Therapeutics. She is interested in evaluating strategies to reduce the risk of neurodevelopmental disorders such as autism. Research indicates maternal immune activation and placental inflammation may disrupt fetal brain development and influence long-term outcomes. Building on findings from preclinical studies, including Zika virus models, she hopes to explore pregnancy-compatible immune therapeutics that could stabilize the intrauterine environment, minimize oxidative stress, and protect neurodevelopment. This project remains exploratory but demonstrates her broader vision of preventive strategies safeguarding maternal–fetal health.